Romuald Corbau
Technik-/Wissenschafts-/F&E-Leiter bei ADVERUM BIOTECHNOLOGIES, INC.
Aktive Positionen von Romuald Corbau
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 29.01.2024 | - |
Karriereverlauf von Romuald Corbau
Ehemalige bekannte Positionen von Romuald Corbau
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| FREELINE THERAPEUTICS HOLDINGS PLC | Technik-/Wissenschafts-/F&E-Leiter | - | 20.08.2021 |
GenEdit, Inc.
 GenEdit, Inc. Pharmaceuticals: MajorHealth Technology GenEdit, Inc. develops gene therapies and gene editing-based therapeutics. Its proprietary nanoparticles applies for the development of CRISPR-based therapeutics and gene therapy products for a range of genetic diseases. The company was founded by Kunwoo Lee, Niren Murthy, and Hyo Min Park in 2016 and is headquartered in Berkeley, CA. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von Romuald Corbau
| Université des Sciences et Technologies de Lille | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 3 |
| Vereinigtes Königreich | 2 |
| Frankreich | 2 |
Operativ
| Chief Tech/Sci/R&D Officer | 3 |
| Graduate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
GenEdit, Inc.
GenEdit, Inc. Pharmaceuticals: MajorHealth Technology GenEdit, Inc. develops gene therapies and gene editing-based therapeutics. Its proprietary nanoparticles applies for the development of CRISPR-based therapeutics and gene therapy products for a range of genetic diseases. The company was founded by Kunwoo Lee, Niren Murthy, and Hyo Min Park in 2016 and is headquartered in Berkeley, CA. | Health Technology |
- Börse
- Insiders
- Romuald Corbau
- Erfahrung
